The global distribution and the average annual percentage changes (AAPCs) in age-standardized incidence rates (ASRs, per 100.000) of kidney cancer at the national level. (a ASR of kidney cancer in 2017; b ASR of kidney cancer in 2030; c AAPC of kidney cancer ASR between 1990 and 2017; d AAPC of kidney cancer ASR between 2018 and 2030).
Tumor burden and metastatic disease sites are well-established prognostic factors in many malignancies, including metastatic Renal Cell Carcinoma (mRCC)
We aimed to evaluate the impact of bone metastasis (BM) location on clinical outcome of mRCC patients.
Figure 1: Overall Survival for the entire patient cohort.
Figure 2: Overall Survival: a Comparison Between Groups with Spinal Bone Metastasis and Non-spinal Bone Metastasis.
Purpose: Automated performance metrics provide a novel approach to the assessment of surgical performance. Herein, we present a construct validation of automated performance metrics during robotic assisted partial nephrectomy....
The LARCG (Latin American Renal Cancer Group) is a group of scientific and educational, multicentric, multidisciplinary and independent. It is not for profit, and the term of operation is indeterminate. It consists of Urologists, Pathologists and Oncologists, as well as professionals and researchers related to the field of health, belonging to Hospitals in Latin America, Spain and the United States.
#ASCO21 @ASCO Plenary #LBA5 : Keynote-564 trial results just out 👉https://bit.ly/3g4mQ6Q ,in patients with high risk resected #kidneycancer: Pembrolizumab significantly improves disease free survival. Practice changing data Congrats @DrChoueiri @tompowles1 @OncoAlert
3Just out in @JAMANetworkOpen: Sites of metastasis vary by histology in mRCC and are associated with OS. Thanks to all @IMDConline collaborators!
@DrDanielHeng @DrChoueiri @ChunLGan @g_develasco @CPRT65 @FDonskov @montypal @ravikanesvaran @NeilReaumeMD
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2775361
